Novel combinatorial transdermal drug delivery of alendronate with risedronate for the treatment of osteoporosis

Fanguo  Kong; Bin  Jia; Peng  Cui; Duojun Wang

doi:10.18388/abp.2019_2863

Novel combinatorial transdermal drug delivery of alendronate with risedronate for the treatment of osteoporosis

Fanguo Kong Department of minimally invasive spine surgery, Luoyang Orthopedic Hospital of Henan Province, Zhengzhou City, Henan, 450018, China https://orcid.org/0000-0001-7165-0383
Bin Jia Integrated Orthopedic Department of Traditional Chinese Medicine (TCM) and Western Medicine Hong-Hui Hospital, Xi’an Jiaotong University College of Medicine, Xi’an City, Shaanxi, 710054, China https://orcid.org/0000-0001-7739-7665
Peng Cui Deparment of Orthopedics, Beijing Tongren Hospital, Biejing, China
Duojun Wang Department of Orthopedics, Shidong Hospital, Yangpu District, Shanghai, 200438, China https://orcid.org/0000-0003-3013-6809

DOI: https://doi.org/10.18388/abp.2019_2863

Abstract

The presented investigation explores the efficiency of novel transdermal drug delivery system of combination of two drugs i.e risedronate and alendronate in the treatment of osteoporosis. The nanoparticulate transdermal patch was prepared using PLGA as principle polymer which has been found to be suitable for drug delivery. The novel formulation system was found to be more efficient in lowering and maintaining the plasma calcium at a normal level when compared to a pure drug in a study carried out on an excised rat skin.

pdf
html

Published

2019-12-17

Issue

Vol. 66 No. 4 (2019): Part I and Part II - FEBS

Section

Articles

Acta Biochimica Polonica is an OpenAccess quarterly and publishes four issues a year. All contents are distributed under the Creative Commons Attribution-ShareAlike 4.0 International (CC BY 4.0) license. Everybody may use the content following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.